yes you did you clearly stated that Aptoll was phase 2 and hence they recieved non dilutive funding for mycardiol infarction. They are in preclinical stages like NYR and recieved 6 million in non dilutive funding so far for cardiovascular indication.
Secondly they dose first human in 4 weeks. You will know of the side effects within 10 days of dosing as per phase 1 study. Don’t worry there is a ton of news flow these next few weeks and straight into Walter Reed results straight after. Going multiples and the geniuses that are selling for a pip will be soaked and this will still run on the clearence of safety and Walter Reed just before FDA submission for phase 2. 23 million market cap laughable but will change in the period ahead
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)